NCT03988192 (Immuno-VOC) is a NA clinical trial of VOC analysis in Lung Cancer, Non-small Cell, sponsored by Hopital Foch.

Who is sponsoring NCT03988192?

NCT03988192 is sponsored by Hopital Foch.

What drugs are being tested in NCT03988192?

Interventions in NCT03988192: VOC analysis.

What condition does NCT03988192 study?

NCT03988192 studies Lung Cancer, Non-small Cell.

Is NCT03988192 still recruiting?

NCT03988192 is currently terminated. Last updated 27 January 2022.

Last reviewed 2022-01-27 · How we verify

NCT03988192: Immuno-VOC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response

Terminated NA Last updated 27 January 2022

What this trial tests

NA trial testing VOC analysis in Lung Cancer, Non-small Cell in 60 participants. Terminated before completion.

Timeline

28 August 2018

Primary endpoint
26 May 2021

26 May 2021

Quick facts

Lead sponsor	Hopital Foch
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	60
Start date	28 August 2018
Primary completion	26 May 2021
Estimated completion	26 May 2021
Sites	1 location across France

Drugs / interventions tested

VOC analysis

Conditions studied

Lung Cancer, Non-small Cell — all drugs for Lung Cancer, Non-small Cell →

Sponsor

Hopital Foch — full company profile →

Who can join

18 and older, any sex, with Lung Cancer, Non-small Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases. Immunotherapy is a new therapeutic approach used in non small cell lung cancer in a late stage. VOC analysis could allow to identify biomarkers of early response to immunotherapy. The study of VOC could help in the optimisation of immunotherapy prescription in lung cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The smell of lung disease: a review of the current status of electronic nose technology.
van der Sar IG, Wijbenga N, Nakshbandi G, Aerts JGJV, et al · · 2021 · cited 41× · PMID 34535144 · DOI 10.1186/s12931-021-01835-4

Verify or expand the search:

Other trials of VOC analysis

Trials testing the same drug.

NCT05029349 — Exploration of the VOLATOLOM in the Stable Severe COPD (Chronic Obstructive Pulmonary Disease) · NA · unknown
NCT03988790 — Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled · NA · unknown

Other recruiting trials for Lung Cancer, Non-small Cell

Currently open trials in the same condition.

NCT06538012 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer · Phase 1, PHASE2 · recruiting
NCT04940936 — Shared Decision Making on Radiation Dose for Lung Malignancies · NA · recruiting
NCT05598528 — Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Adv · recruiting
NCT04986670 — NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer · NA · active not recruiting

Other Hopital Foch trials

Trials by the same sponsor.

NCT06980844 — Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies · NA · not yet recruiting
NCT06757244 — DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer · Phase 2 · recruiting
NCT06631794 — Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students · not yet recruiting
NCT06533436 — Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation · NA · recruiting
NCT06476002 — Analysis of the Understanding of the French Version of the Vulvar Pain Assessment Questionnaire · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03988192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hopital Foch
Last refreshed: 27 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing